Abstract 48P
Background
A2A receptor (A2AR) is a key mediator of adenosine immunosuppression. Inupadenant is a highly selective A2AR antagonist, which maintains full potency at the high levels of adenosine found in tumors. We recently reported that B cells are a novel cellular target of inupadenant (Martinoli et al., AACR 2023). Here, we further investigate how inupadenant modulates humoral responses in vitro, ex vivo and in vivo.
Methods
Inupadenant was assessed through: in vitro generation of antibody secreting cells (ASCs) from memory B cells isolated from human PBMCs; ex vivo tumor culture of tumor slices derived from human lung cancer; and single cell RNA sequencing (scRNAseq) on isolated healthy tonsil B cells. The A2AR agonist CGS-21680 (in vitro and scRNAseq) or ATP (ex vivo) were added to trigger A2AR signaling, and B cells were stimulated with CpG (scRNAseq) or CD40L (ex vivo). Cell cultures were assessed by flow cytometry and Legendplex. The CT26-OVA model was used to study tumor-targeted immunoglobulin (Ig) production and immune infiltration by ELISA and RNAseq.
Results
Inupadenant rescued the A2AR-mediated inhibition of B cell maturation into ASCs and Ig production in both in vitro and ex vivo systems. In CT26-OVA mice, inupadenant increased OVA-specific IgGs in blood and tumor, as well as B cells and ASCs in spleen and tumor. Besides ASCs, germinal center (GC) B cells were the main B cell subset affected by A2AR signaling in human tonsil, as supported by (i) the highest number of differentially expressed genes observed in these subsets after CGS-21680 stimulation, and (ii) by their highest expression of the A2AR gene, ADORA2A. Inupadenant completely reverted the effect of CGS-21680 in ASCs and GC B cells, including the expression of AICDA, a critical gene for somatic hypermutation and class-switch recombination in GCs.
Conclusions
These data support the notion that inupadenant restores or even potentiates B cell maturation toward ASCs and GC reactions in both secondary lymphoid organs as well as tumor in the presence of A2AR signaling. This process is essential to produce high affinity antibodies and potentially for sustained anti-tumor immunity. Additional work is ongoing to confirm this novel mechanism in inupadenant-treated patients.
Legal entity responsible for the study
iTeos Therapeutics.
Funding
iTeos Therapeutics.
Disclosure
P. Tieppo, M. Mercier, S. Jung, D. Carbonez, L. Chaible, R. Marillier, F. Strozzi, H. Shehade, Y. McGrath, M. Rossetti: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. M. Dieu-Nosjean: Financial Interests, Personal, Speaker, Consultant, Advisor: iTeos Therapeutics.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session